NEW YORK (GenomeWeb News) – Myriad Genetics said after the close of the market on Monday that it has signed an agreement to provide its BRACAnalysis test as a companion diagnostic for a cancer therapeutic being developed by Tesaro.
Registering provides access to this and other free content.
Already have an account?Login Now.
The New York Times' George Johnson muses on cancer's roots in multicellularity.
The San Diego Union Tribune wonders whether Medicare is ready for personalized medicine.
Jun Wang, the chief executive of BGI, has stepped down.
In PLOS this week: locus linked to non-syndromic hearing loss, phylogenetic relationships of Klebsiella pneumoniae isolates, and more.